Existing marketed therapies for Alzheimer’s disease target symptoms in the late stages, but don’t arrest progression. With Alzheimer’s disease increasing rapidly in frequency there is an urgent need to discover new drugs that treat affected patients. However, all recent attempts to develop an effective treatment for Alzheimer’s disease have failed, and there is a growing lack of confidence in the efficacy of combating the well-established targets amyloid or tau, leading to the need for a new approach.
Neuro-Bio has discovered the T14 pathway that appears to be the root cause of degeneration and can be monitored in blood as a potential biomarker of disease progression and treatment response. T14 is a 14 amino acid peptide derived from the C terminus of acetylcholinesterase that drives the secondary production of amyloid and tau, induces cognitive impairment in rats and can be intercepted pharmaceutically to stabilize any further cell loss.
T14 is distributed throughout the primarily vulnerable cells, is doubled in the post-mortem Alzheimer mid-brain and is increased significantly in Alzheimer CSF. T14 acts through binding to a modulatory site on the alpha-7 receptor where it enhances calcium entry, thereby inducing excitotoxicity and further proliferation of the receptor itself, thus perpetuating a feedforward cycle of neurodegeneration.
Neuro-Bio has been granted a patent on a novel manner of inhibiting the binding of T14, by means of a cyclized peptide, which has prompted the discovery of linear short peptide inhibitors, now also filed. The company is developing potential therapeutic drugs using the linear peptide variants as templates to design small molecules that will be able to cross the blood brain barrier, for the first time stabilize cell loss and hence eventually treat this debilitating disease effectively. If this treatment were given at the presymptomatic stage, when the T14 blood test revealed neurodegeneration was already underway, then the symptoms may never appear leading to an effective cure for the disease.